| 1 | Enhanced production of recombinant coxsackievirus A16 using a serum-free HEK293A suspension culture system for bivalent enterovirus vaccine development | 1.8 | 0 | Citations (PDF) |
| 2 | Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system | 2.6 | 3 | Citations (PDF) |
| 3 | The stability and immunogenicity of formalin-inactivated Enterovirus A71 whole virion vaccine after ten years of low temperature storage | 3.2 | 1 | Citations (PDF) |
| 4 | Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies | 4.5 | 25 | Citations (PDF) |
| 5 | Separation and purification of highly infectious enterovirus A71 particles using a strong anion-exchange column | 3.7 | 3 | Citations (PDF) |
| 6 | Glycan‐masking hemagglutinin antigens from stable CHO cell clones for H5N1 avian influenza vaccine development | 3.9 | 20 | Citations (PDF) |
| 7 | Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development | 3.2 | 11 | Citations (PDF) |
| 8 | Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development | 3.8 | 10 | Citations (PDF) |
| 9 | Mutations in VP1 and 5′-UTR affect enterovirus 71 virulence | 3.5 | 20 | Citations (PDF) |
| 10 | Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture | 3.2 | 14 | Citations (PDF) |
| 11 | Maternal immunization with a recombinant adenovirus-expressing fusion protein protects neonatal cotton rats from respiratory syncytia virus infection by transferring antibodies via breast milk and placenta | 2.3 | 10 | Citations (PDF) |
| 12 | Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease | 4.1 | 49 | Citations (PDF) |
| 13 | Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology | 3.8 | 13 | Citations (PDF) |
| 14 | Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles | 3.8 | 39 | Citations (PDF) |
| 15 | Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design | 3.8 | 8 | Citations (PDF) |
| 16 | Immunogenicity of an adeno-vector vaccine expressing the F protein of a respiratory syncytial virus manufactured from serum-free suspension culture | 3.8 | 6 | Citations (PDF) |
| 17 | Recombinant Adeno-Vaccine Expressing Enterovirus 71-Like Particles against Hand, Foot, and Mouth Disease | 3.1 | 24 | Citations (PDF) |
| 18 | Review of Enterovirus 71 Vaccines | 5.4 | 129 | Citations (PDF) |
| 19 | Long-Term Immunogenicity Studies of Formalin-Inactivated Enterovirus 71 Whole-Virion Vaccine in Macaques | 2.4 | 8 | Citations (PDF) |
| 20 | Toll-Like Receptor 9-Mediated Protection of Enterovirus 71 Infection in Mice Is Due to the Release of Danger-Associated Molecular Patterns | 3.7 | 41 | Citations (PDF) |
| 21 | Immunogenicity Studies of Bivalent Inactivated Virions of EV71/CVA16 Formulated with Submicron Emulsion Systems | 2.5 | 18 | Citations (PDF) |
| 22 | Delivery of Human EV71 Receptors by Adeno-Associated Virus Increases EV71 Infection-Induced Local Inflammation in Adult Mice | 2.5 | 3 | Citations (PDF) |
| 23 | Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases | 3.2 | 68 | Citations (PDF) |
| 24 | A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine | 3.2 | 73 | Citations (PDF) |
| 25 | Caveolar Endocytosis Is Required for Human PSGL-1-Mediated Enterovirus 71 Infection | 3.7 | 49 | Citations (PDF) |
| 26 | Monoclonal Antibodies for Diagnosis of Enterovirus 71 | 1.0 | 9 | Citations (PDF) |
| 27 | Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV | 3.2 | 7 | Citations (PDF) |
| 28 | Human SCARB2 Transgenic Mice as an Infectious Animal Model for Enterovirus 71 | 2.4 | 96 | Citations (PDF) |
| 29 | Protective Efficacy of VP1-Specific Neutralizing Antibody Associated with a Reduction of Viral Load and Pro-Inflammatory Cytokines in Human SCARB2-Transgenic Mice | 2.4 | 19 | Citations (PDF) |
| 30 | Heat Shock protein 90: Role in Enterovirus 71 Entry and Assembly and Potential Target for Therapy | 2.4 | 65 | Citations (PDF) |
| 31 | Formalin-Inactivated EV71 Vaccine Candidate Induced Cross-Neutralizing Antibody against Subgenotypes B1, B4, B5 and C4A in Adult Volunteers | 2.4 | 81 | Citations (PDF) |
| 32 | Immunological Evaluation and Comparison of Different EV71 Vaccine Candidates | 3.5 | 30 | Citations (PDF) |
| 33 | Selection and characterization of vaccine strain for Enterovirus 71 vaccine development | 3.2 | 59 | Citations (PDF) |
| 34 | Human SCARB2-Mediated Entry and Endocytosis of EV71 | 2.4 | 70 | Citations (PDF) |
| 35 | Pilot Scale Production of Highly Efficacious and Stable Enterovirus 71 Vaccine Candidates | 2.4 | 56 | Citations (PDF) |
| 36 | Immunological and Biochemical Characterization of Coxsackie Virus A16 Viral Particles | 2.4 | 52 | Citations (PDF) |
| 37 | Identification and characterization of a cross-neutralization epitope of Enterovirus 71 | 3.2 | 169 | Citations (PDF) |
| 38 | Purification and Characterization of Enterovirus 71 Viral Particles Produced from Vero Cells Grown in a Serum-Free Microcarrier Bioreactor System | 2.4 | 114 | Citations (PDF) |
| 39 | Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates | 1.7 | 23 | Citations (PDF) |
| 40 | Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process | 1.7 | 23 | Citations (PDF) |
| 41 | High Genetic Stability of Dengue Virus Propagated in MRC-5 Cells as Compared to the Virus Propagated in Vero Cells | 2.4 | 14 | Citations (PDF) |
| 42 | High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture | 3.2 | 70 | Citations (PDF) |
| 43 | Mosquito and mammalian cells grown on microcarriers for four-serotype dengue virus production: Variations in virus titer, plaque morphology, and replication rate | 3.9 | 11 | Citations (PDF) |
| 44 | Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development | 3.2 | 70 | Citations (PDF) |
| 45 | The use of glucose to regulate pH values of culture media and increase the production of baculovirus (BmNPV) and foreign protein (HBsAg) | 3.9 | 1 | Citations (PDF) |
